Among patients with multiple sclerosis treated long-term with ocrelizumab, interstitial lung disease developed after a mean of 10.5 years, mainly as organizing pneumonia with variable outcomes.

This case series describes 6 cases of interstitial lung disease among patients with multiple sclerosis receiving long-term treatment with ocrelizumab.